SATURDAY, OCTOBER 1, 2016

NanoViricides signs agreement with PHE

NanoViricides, Inc., a West Haven, Connecticut-based development stage company, announced a confidential disclosure agreement on Monday with Public Health England, an executive agency of the U.K. Department of Health.

The agreement will enable the scientists at PHE to develop a specific proposal to test various nanoviricides, such as FluCide, against viruses considered to be of mutual interest to both organizations. The first two viruses of mutual interest are the MERS coronavirus and the H7N9 influenza virus.

The MERS CoV is similar to the SARS virus that infected 8,000 people and killed approximately 800 individuals a decade ago. The H7N9 influenza virus is currently circulating in China. Both viruses have high case fatality rates.

PHE will test the nanoviricide antiviral drug candidates in biosafety level three and four facilities. The facilities are meant to contain and allow for the safe handling of organisms that can be threatening to public health.

Public Health England is the British government's equivalent to the U.S. Centers for Disease Control and Prevention. The agency, which took up full responsibilities on April 1, works with local and national government, the U.K. National Health Service and the healthcare industry to protect and improve the nation's health and support healthier choices. The agency also plans to address inequalities by concentrating on removing impediments to good health.

NanoViricides, Inc., develops special purpose nanomaterials for viral therapy. The company's novel nanoviricide class of drug candidates attack enveloped virus particles and dismantle them. NanoViricides is developing drugs against multiple viral diseases, such as H5N1 bird flu, H1N1 swine flu, seasonal influenza, oral and genital herpes, viral diseases of the eye, rabies, dengue fever, Ebola virus, hepatitis C and HIV.